Repositioning Candidate Details
| Candidate ID: | R0313 |
| Source ID: | DB00865 |
| Source Type: | approved; illicit |
| Compound Type: | small molecule |
| Compound Name: | Benzphetamine |
| Synonyms: | (+)-benzphetamine; (+)-N-benzyl-N,α-dimethylphenethylamine; (+)-N,α-dimethyl-N-(phenylmethyl)-benzeneethanamine; (S)-(+)-benzphetamine; (S)-(+)-N-benzyl-N,α-dimethylphenethylamine; (S)-benzphetamine; (αS)-N,α-dimethylphenethylamine; Benzaphetamine; Benzfetamine; Benzphetamine; Benzylamphetamine; d-N-methyl-N-benzyl-β-phenylisopropylamine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine |
| Molecular Formula: | C17H21N |
| SMILES: | C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) |
| CAS Number: | 156-08-1 |
| Molecular Weight: | 239.3553 |
| DrugBank Indication: | For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction |
| DrugBank Pharmacology: | Benzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for. |
| DrugBank MoA: | The mechanism of action of these drugs is not fully understood, however it may be similar to that of amphetamines. Amphetamines stimulate noepinephrine and dopamine release in nerve endings in the lateral hypothalamic feeding centre, decreasing appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors. |
| Targets: | Synaptic vesicular amine transporter inducer; Alpha-2A adrenergic receptor agonist; Alpha-1A adrenergic receptor agonist; Sodium-dependent dopamine transporter inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |